Covered recipient · General Payments record
CLAUDE RUMSEY
General Payments · PY2018–2024
$9,709.75
- Reported across 214 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $909.23 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $530.95 | 12 |
| REVANCE THERAPEUTICS, INC. | $225.53 | 4 |
| TELA Bio, Inc. | $138.72 | 1 |
| Galderma Laboratories, L.P. | $14.03 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $1.77 | 02/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105988523 | CMS |
| ABBVIE INC. | $119.00 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105988525 | CMS |
| ABBVIE INC. | $16.19 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105988527 | CMS |
| ABBVIE INC. | $17.36 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105988529 | CMS |
| ABBVIE INC. | $5.87 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105988531 | CMS |
| ABBVIE INC. | $17.50 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105988533 | CMS |
| ABBVIE INC. | $6.04 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105988535 | CMS |
| ABBVIE INC. | $24.67 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105988537 | CMS |
| ABBVIE INC. | $131.68 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105988539 | CMS |
| ABBVIE INC. | $34.12 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105988541 | CMS |
| ABBVIE INC. | $150.00 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105988543 | CMS |
| ABBVIE INC. | $6.75 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105988545 | CMS |
| Galderma Laboratories, L.P. | $14.03 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145325271 | CMS |
| REVANCE THERAPEUTICS, INC. | $80.19 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147928117 | CMS |
| REVANCE THERAPEUTICS, INC. | $113.66 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147928119 | CMS |
| REVANCE THERAPEUTICS, INC. | $11.36 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147928121 | CMS |
| REVANCE THERAPEUTICS, INC. | $20.32 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147928123 | CMS |
| TELA Bio, Inc. | $138.72 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154189146 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.